Turn recording back on
Clinical development of anti-RANKL therapy.
Schwarz EM, Ritchlin CT.
Arthritis Res Ther. 2007;9 Suppl 1:S7. Review.
PMID: 17634146 [PubMed - indexed for MEDLINE]
Related Articles Free article in PMC
[Therapeutic agents for disorders of bone and calcium metabolism--Denosumab, a fully human monoclocal antibody-targeting RANKL as a therapy for cancer-induced bone diseases]
Mera K, Ito K.
Clin Calcium. 2007 Jan;17(1):37-46. Review. Japanese.
PMID: 17211092 [PubMed - indexed for MEDLINE]
Related Articles
Denosumab: RANKL inhibition in the management of bone loss.
Hamdy NA.
Drugs Today (Barc). 2008 Jan;44(1):7-21. Review.
PMID: 18301800 [PubMed - indexed for MEDLINE]
RANK ligand inhibition with denosumab for the management of osteoporosis.
Lewiecki EM.
Expert Opin Biol Ther. 2006 Oct;6(10):1041-50. Review.
PMID: 16989586 [PubMed - indexed for MEDLINE]
Cell-based assay strategy for identification of motif-specific RANK signaling pathway inhibitors.
Chen T, Feng X.
Assay Drug Dev Technol. 2006 Aug;4(4):473-82. Review.
PMID: 16945019 [PubMed - indexed for MEDLINE]
Inhibition of RANK/RANKL signal transduction pathway: a promising approach for osteoporosis treatment.
Bai YD, Yang FS, Xuan K, Bai YX, Wu BL.
Med Hypotheses. 2008 Aug;71(2):256-8. Epub 2008 Apr 28.
PMID: 18445511 [PubMed - indexed for MEDLINE]
The RANK/RANKL/OPG triad in cancer-induced bone diseases.
Dougall WC, Chaisson M.
Cancer Metastasis Rev. 2006 Dec;25(4):541-9. Review.
PMID: 17180711 [PubMed - indexed for MEDLINE]
RANKL inhibition in the treatment of bone metastases.
Lipton A, Jun S.
Curr Opin Support Palliat Care. 2008 Sep;2(3):197-203. Review.
PMID: 18685421 [PubMed - indexed for MEDLINE]
Investigating the interaction between osteoprotegerin and receptor activator of NF-kappaB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways.
Vitovski S, Phillips JS, Sayers J, Croucher PI.
J Biol Chem. 2007 Oct 26;282(43):31601-9. Epub 2007 Aug 15.
PMID: 17702740 [PubMed - indexed for MEDLINE]
Signaling axis in osteoclast biology and therapeutic targeting in the RANKL/RANK/OPG system.
Tanaka S.
Am J Nephrol. 2007;27(5):466-78. Epub 2007 Jul 25. Review. Erratum in: Am J Nephrol. 2007;27(5):544.
PMID: 17652963 [PubMed - indexed for MEDLINE]
DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
Mori K, Le Goff B, Charrier C, Battaglia S, Heymann D, Rédini F.
Bone. 2007 Apr;40(4):981-90. Epub 2006 Dec 28.
PMID: 17196895 [PubMed - indexed for MEDLINE]
[Monoclonal antibody targeting RANKL as a therapy for cancer-induced bone diseases]
Dougall W, Chaisson M.
Clin Calcium. 2006 Apr;16(4):627- 35. Review. Japanese.
PMID: 16582514 [PubMed - indexed for MEDLINE]
Targeting the RANK/RANKL/OPG signaling pathway: a novel approach in the management of osteoporosis.
Curr Opin Investig Drugs. 2007 Apr;8(4):299-303. Review.
PMID: 17458179 [PubMed - indexed for MEDLINE]
RANK ligand as a therapeutic target for bone metastases and multiple myeloma.
Roodman GD, Dougall WC.
Cancer Treat Rev. 2008 Feb;34(1):92-101. Epub 2007 Oct 26. Review.
PMID: 17964729 [PubMed - indexed for MEDLINE]
Key roles of the OPG-RANK-RANKL system in bone oncology.
Baud'huin M, Duplomb L, Ruiz Velasco C, Fortun Y, Heymann D, Padrines M.
Expert Rev Anticancer Ther. 2007 Feb;7(2):221-32. Review.
PMID: 17288531 [PubMed - indexed for MEDLINE]
Targeting the receptor activator of nuclear factor-kappaB (RANK) ligand in prostate cancer bone metastases.
Saad F, Markus R, Goessl C.
BJU Int. 2008 May;101(9):1071-5. Epub 2007 Dec 5. Review.
PMID: 18070191 [PubMed - indexed for MEDLINE]
The new concept of periodontal disease pathogenesis requires new and novel therapeutic strategies.
Taubman MA, Kawai T, Han X.
J Clin Periodontol. 2007 May;34(5):367-9.
PMID: 17448041 [PubMed - indexed for MEDLINE]
Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.
Kearns AE, Khosla S, Kostenuik PJ.
Endocr Rev. 2008 Apr;29(2):155-92. Epub 2007 Dec 5. Review.
PMID: 18057140 [PubMed - indexed for MEDLINE]
[RANKL inhibition as therapy for joint damage]
Akama H.
Nihon Rinsho Meneki Gakkai Kaishi. 2007 Oct;30(5):404-7. Review. Japanese.
PMID: 17984581 [PubMed - indexed for MEDLINE]
Clinical potential of RANKL inhibition for the management of postmenopausal osteoporosis and other metabolic bone diseases.
Delmas PD.
J Clin Densitom. 2008 Apr-Jun;11(2):325-38. Epub 2008 Apr 2. Review.
PMID: 18375161 [PubMed - indexed for MEDLINE]